Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

222 results about "Memory impairment" patented technology

Memory impairment or memory loss may be defined as lack of a person’s ability to consistently recollect information to the extent of impairing the daily activities of the person. It can be acute or progressive and chronic.

Compositions and methods for treating and preventing memory impairment using citicoline

This invention relates to compositions and methods for preventing and treating cognitive dysfunction or memory impairment. The compositions include an effective amount of citicoline, or pharmaceutically-acceptable salts thereof, and one or more of the compounds selected from the group consisting of linoleic acid and linolenic acid. Other compositions of this invention include an effective amount of citicoline, or pharmaceutically-acceptable salt thereof, wherein said citicoline is metabolized to form at least one of cytidine, uridine, and choline. Still other compositions of this invention include effective amounts of choline, cytidine, and / or uridine, or their pharmaceutically-acceptable salts. This invention also encompasses methods for preparing these compositions.
Owner:MASSACHUSETTS INST OF TECH

Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment

InactiveUS20080287372A1Prevention of loss of cognitive functionLower metabolismBiocideNervous disorderMemory disorderMedium-chain triglyceride
This invention relates to the field of therapeutic agents for the treatment of Age-Associated Memory Impairment (AAMI). In particular, the present invention utilizes compositions comprising at least one compound capable of elevating ketone body concentrations in a mammal (e.g., ketogenic compounds), administered in an amount effective for treatment or prevention of loss of cognitive function caused by reduced neuronal metabolism in AAMI. In one embodiment, the composition includes medium chain triglycerides (MCT). In another embodiment, the compositions are administered in the presence of carbohydrate. The present invention also relates to oral dosage forms, in particular, a nutritional drink comprising at least one compound capable of elevating ketone body concentrations in a mammal.
Owner:CERECIN INC

Animal model simulating neurologic disease

The present invention relates to the development of a pharmacological non-human animal model that associates memory loss to histopathological features found in the brain of a subject having Alzheimer's Disease. In one embodiment, a four-week continuous infusion of a Fe2+, Aβ42 and buthionine sulfoximine (FAB) solution in the left ventricle of young adult Long-Evans rats induced memory impairment accompanied by increased hyperphosphorylated Tau protein levels in cerebrospinal fluid. Brains from treated animals displayed neuritic plaques, tangles, neuronal loss, astrogliosis and microgliosis in hippocampus and cortex. The present invention may be utilized in evaluating preventive, therapeutic and diagnostic means for neurologic diseases.
Owner:SAMARITAN PHARMA +1

Formulation of a mixture of Free-B-Ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments

The present invention provides a novel method for preventing and treating memory and cognitive impairment resulting from oxidative stress, inflammation and the process of aging, as well as, neurodegenerative conditions. The method is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and / or isolated from a single plant or multiple plants to a host in need thereof. The present also includes a novel method for simultaneously inhibiting expression of pro-inflammatory cytokines, preventing ROS generation and augmenting anti-oxidant defenses. The activity of this composition is conducive to ultimately preserving cognitive function and providing a level of neuroprotection.
Owner:UNIGEN PHARM INC

3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses

This invention relates to the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for higher order behaviors. These brain networks are involved in cognitive abilities related to memory impairment, such as is observed in a variety of dementias and in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia and affective disorders. In a particular aspect, the present invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.
Owner:CORTEX PHARMA

Application of hydrogen sulfide donor to preparation of medicine for treating central nervous system disease

The invention belongs to the field of pharmacy, and relates to application of a hydrogen sulfide donor to the preparation of a medicine for treating central nervous system disease, in particular to application of the hydrogen sulfide donor, namely sodium hydrosulfide, or allyl cysteine and analogues thereof to the preparation of the medicine for treating the central nervous system disease. Integral animal model experiments prove that the sodium hydrosulfide and propargyl cysteine can reduce the learning and memory impairment of rats, increase the content of hydrogen sulfide in hippocampus tissues of the rats, inhibit the messenger ribonucleic acid (mRNA) expression of a tumor necrosis factor alpha and a receptor I thereof, inhibit an inflammatory mediator in the hippocampus tissues of rats with dementia and inhibit inflammation-related enzymes in the hippocampus tissues of the rats, and can be used as a medicine for treating Alzheimer disease and other inflammation-related central nervous system degenerative diseases such as Parkinson disease.
Owner:FUDAN UNIV

Memory in subjects with mini-mental state examination of 24-26

InactiveUS20100331258A1Reduce needReduce dosage of treatmentBiocideNervous disorderDocosahexaenoic acidModerate dementia
The invention thus pertains to the use of a composition comprising: (a) uridine or uridine phosphate; and (b) docosahexaenoic acid and / or eicosapentaenoic acid, for improving memory and / or the treatment or prevention of impaired memory function, in a subject with a mini-mental state examination of 24-26, wherein said composition is enterally administered to the subject. In the MMSE test, any score of 27 or higher (out of 30) is effectively normal. In the patients with dementia, 20-26 indicates mild dementia, 10-19 moderate dementia, and below 10 severe dementia. It was the present inventors' belief that within the group of 20-26, the memory impairment in the sub-group of 24-26 may even be reversible, as the pathological pathways have just started to develop. In this group of subjects the pathological pathways have just started to develop. Clinical studies show excellent results for this subgroup.
Owner:NUTRICIA

Di-substituted amides for enhancing glutamatergic synaptic responses

This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as in disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin, or where the respiratory depression results form a medical condition such as central sleep apnea, stroke-induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi's syndrome and drowning. In a particular aspect, the invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.
Owner:CORTEX PHARMA INC

Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same

The present invention relates generally to novel hydantoin derivative compounds, pharmaceutical compositions containing such compounds, and methods for their use in preventing and / or treating neurological disorders, including physically damaged nerves and neurodegenerative diseases; for treating alopecia and promoting hair growth; for treating vision disorders and / or improving vision; for treating memory impairment and / or enhancing memory performance; and for treating sensorineural hearing loss by administering such compounds.
Owner:GPI NIL HLDG INC +1

Applications of 1 type cysteinyl leukotriene receptor antagonist on preparation of medicament for treating the Alzheimer disease

InactiveCN103505731ADecreased memory functionIncreased Aβ levelsNervous disorderHeterocyclic compound active ingredientsCysteinyl leukotrienesOral medication
The invention relates to applications of a cysteinyl leukotriene receptor antagonist (CysLT1R) on preparation of a medicament for treating the Alzheimer disease. Research finds that intracerebral CysLT1R mediates A beta aggregation and dysmnesia; and by oral medication, CysLT1R antagonists such as pranlukast, zafirlukast and montelukast can improve mice memory impairment caused by A beta. The CysLT1R antagonists such as pranlukast, zafirlukast and montelukast, and analogs thereof such as iralukast, ablukast, imitrodast, pobilukast, cinalukast, verlukast, pemirolast and ibudilast, have significant protection effect on primarily-cultured mice neuron damage caused by A beta. The CysLT1R antagonists such as pranlukast, zafirlukast and montelukast, and the analogs thereof such as iralukast, ablukast, imitrodast, pobilukast, cinalukast, verlukast, pemirolast and ibudilast, can be used for preparing anti-AD medicaments.
Owner:CHINA PHARM UNIV

Medicinal compositions improving brain function and method for improving brain function

An alkyl ether derivative represented by the formula: wherein R1, R2, R3, R4, m and n are as defined in the specification, or salts thereof exhibits synergistically improved anti-hypoxic activity when combined with a compound having an acetylcholine esterase inhibitory activity. Therefore, the combination according to the present invention is useful as a method for improving cerebral function. Further, a pharmaceutical composition containing the compound relating to the combination according to the present invention is useful for treatment and prevention of dysfunction of cerebral acetylcholine neurons in the sequelae of cerebrovascular dementia, senile dementia, Alzheimer's disease and ischemic cerebral lesion and in the cerebral apoplexy or the memory impairment caused by selective neuronal death.
Owner:TOYAMA CHEM CO LTD

Memory tests using item-specific weighted memory measurements and uses thereof

This invention relates to a method for increasing the usefulness, sensitivity and specificity of tests that measure memory and facets of memory, including learning, retention, recall and / or recognition. Specifically, the sensitivity and specificity of such tests are enhanced by selectively weighting the value of specific items recalled by the test subject, either by weighting such items within any specific testing trial or across numerous testing trials. Also disclosed are various methods of reducing ceiling effects in memory tests. The invention also provides improved tests which employ item-specific weighting for the diagnosis of Alzheimer's Disease and other dementia characterized by memory impairment, as well as a method of screening for and evaluating the efficacy of potential therapeutics directed to the treatment of such dementia.
Owner:ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIV

Composition comprising minocycline as an effective component for prevention and treatment of dementia, and learning and memory impairments

The present invention relates to a composition for preventing and treating dementia and memory impairment, which contains minocycline as active ingredient. The composition of the present invention has an effect of inhibiting brain cell death and memory impairment, which are induced by amyloid beta-protein and C-terminal protein. Thus, the composition of the present invention is useful for the prevention and treatment of various dementias, including Alzheimer's disease, and the impairment of learning and memory and cognitive function.
Owner:SUH YOO HUN +4

Di-substituted amides for enhancing glutamatergic synaptic responses

This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as in disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin, or where the respiratory depression results form a medical condition such as central sleep apnea, stroke-induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi's syndrome and drowning. In a particular aspect, the invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.
Owner:CORTEX PHARMA

Methods Of Measuring Head, Neck, and Brain Function And Predicting And Diagnosing Memory Impairment

A computer based method and system forms measurements of brain function and predictions of a likelihood for memory impairment via the use of cameras, including a near-infrared (NIR) spectroscopic device and a camera capturing images in the Red-Green-Blue (RGB) spectrum. The device acquires from a subject measurements of ions, molecules, or combinations thereof at more than one moment in time, as well as amplitude and timing of blood pulsations. Based on the measured molecule or ion concentration, flow, and so forth, a processor assesses the probability of a neuron to form an action potential. Formation of an action potential increases the probability that the subject individual will create a memory.
Owner:LITTELL STEPHANIE

Methods for the improvement of memory and neurological function comprising the administration of compositions that act as inhibitors of the sodium proton (na+ /h+ ) exchanger, subtype 5 (nhe-5)

The present invention comprises the use of pharmaceutical compositions that are effective in the inhibition of the Na+ / H+ exchanger, subtype 5 (NHE-5) as inhibitors of cellular NHE-5 enhance long term potentiation (LTP) and are therefore effective in the treatment of memory impairments, dementing disorders, and for improving memory. Particularly suitable for the treatment of neurodegenerative disorders, memory impairments and dementing disorders, and for improving memory, are the following NHE-5 inhibitors of the formula IWherein the R1-R8 substituents are further defined herein:
Owner:SANOFI AVENTIS SA

Medicinal compositions improving brain function and method for improving brain function

An alkyl ether derivative represented by the formula:wherein R1, R2, R3, R4, m and n are as defined in the specification, or salts thereof exhibits synergistically improved anti-hypoxic activity when combined with a compound having an acetylcholine esterase inhibitory activity. Therefore, the combination according to the present invention is useful as a method for improving cerebral function. Further, a pharmaceutical composition containing the compound relating to the combination according to the present invention is useful for treatment and prevention of dysfunction of cerebral acetylcholine neurons in the sequelae of cerebrovascular dementia, senile dementia, Alzheimer's disease and ischemic cerebral lesion and in the cerebral apoplexy or the memory impairment caused by selective neuronal death.
Owner:TOYAMA CHEM CO LTD

Formulation Of A Mixture Of Free-B-Ring Flavonoids And Flavans For Use In The Prevention And Treatment Of Cognitive Decline And Age-Related Memory Impairments

The present invention provides a novel method for preventing and treating memory and cognitive impairment resulting from oxidative stress, inflammation and the process of aging, as well as, neurodegenerative conditions. The method is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and / or isolated from a single plant or multiple plants to a host in need thereof. The present also includes a novel method for simultaneously inhibiting expression of pro-inflammatory cytokines, preventing ROS generation and augmenting anti-oxidant defenses. The activity of this composition is conducive to ultimately preserving cognitive function and providing a level of neuroprotection.
Owner:UNIGEN

Preparation method of Oxiracetam, product of Oxiracetam and use of product

The invention provides a method for preparing Oxiracetam, which comprises the following steps: performing alkaline treatment of 4-hydroxy-2-pyrrolidone under a water-free condition; reacting the treated 4-hydroxy-2-pyrrolidone with 2-chloroacetamide in an organic solvent in the presence of a catalyst; and after the reaction is finished, performing filtration, distillation and recrystallization to obtain the Oxiracetam. In the method, the final product can be obtained by a one-step reaction, the operation is simple and convenient, and large scale production can be realized. The invention also provides the Oxiracetam obtained by the method, which has the characteristics of high yield, high purity and good treatment effect. The invention also provides the use of the Oxiracetam obtained by the method in the preparation of medicaments for treating brain dysfunction, impaired memory and senile dementia.
Owner:TIANJIN INSTITUTE OF PHARMA RESEARCH

Methods for the treatment of respiratory depression

This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as in disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin, or where the respiratory depression results form a medical condition such as central sleep apnea, stoke-induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi's syndrome and drowning, hi a particular aspect, the invention relates to bicyclic amide compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.
Owner:CORTEX PHARMA

Health-care wine

InactiveCN101125169AImprove memory lossSignificant ability to repair and regenerateDigestive systemAlcoholic beverage preparationForest yamWolfiporia extensa
The present invention relates to a health care wine, in particular to a health care wire which contains the traditional Chinese medicine for nourishing yin, the existing health care wines are mostly the wines for strengthening yang, which can cause the imbalance between yin and yang by excessive drinking; China has a word that yang mainly controls the organs and yin mainly controls body fluids, the excess of yang often causes qi stagnation and blood stasis, so as to cause cardiovascular diseases, hearing loss, memory impairment and alopecia. The components of the present invention include: beverage wine, each 1000 parts by weight of the beverage wine is added with 30 parts of radix rehmanniae glutinosae, 30 parts of radix rehmanniae preparata, 20 parts of common yam rhizome, 20 parts of common macrocarpium fruit, 20 parts of barbary wolfberry fruit, 15 parts of glossy privet fruit, 15 parts of tree peony bark, 20 parts of hawthorn fruit, 30 parts of tuber fleeceflower root, 30 parts of salvia, 30 parts of membranous milkvetch root, 20 parts of Chinese magnoliavine fruit, 15 parts of oriental waterplantain rhizome, 15 parts of Indian buead and 15 parts of kudzuvine root, and all the components are soaked for 25 to 40 days and then the wastes are removed. The product can be used as the health care wine for the treatment of age related hearing loss, alopecia, bad memory and the improvement of the cardiovascular adverse states.
Owner:孙景荣

Bombesin receptor antagonists

Bombesin receptor antagonists are provided which are compounds of formula (I) or pharmaceutically acceptable salts thereof: wherein j, k, l, m, n, q, r, Ar, Ar<1>, R<1>, R<2>, R<3>, R<4>, R<5>, R<6 >and X are as defined in the description. The compounds of the invention have an affinity for the BB1 receptor and some of them also have affinity for the BB2 receptor. Accordingly they may be useful for the diagnosis, prevention, or treatment of male and female sexual dysfunction. They can also be used in the diagnosis, prevention or treatment of anxiety and panic disorders, social phobia, depression, psychoses, sleeping disorders, memory impairment, pulmonary hypertension, lung repair and lung development disorders, cancer including prostate cancer and pancreatic cancer, hepatic porphyria, gastrointestinal secretory disturbances, gastrointestinal disorders including colitis, Crohn's disease and inflammatory bowel disease, emesis, anorexia, pain, seasonal affective disorders, feeding disorders or pruritus.
Owner:WARNER-LAMBERT CO

Huperzine a prodrugs and uses thereof

Disclosed are huperzine A prodrugs and method of synthesis thereof. The invention further relates to methods of treating, preventing or reversing neurodegenerative diseases, such as, Alzheimer's Disease and neuronal dysfunctions, such as, memory impairment using a pharmaceutical composition comprising a huperzine A prodrug as disclosed herein.
Owner:PAN BAI CHUAN

D-ribose for improving depression-like symptoms

InactiveUS20070191287A1Improving depression-like symptomSymptoms improvedBiocideNervous disorderMalaiseMedicine
An agent for improving depression-like symptoms comprising D-ribose, which may improve an alleviate various symptoms such as hypobulia, general fatigue, sluggishness, enervation, deterioration in concentration, memory impairment, abnormal sensation / obtundation such as impaired sight, decline in thinking power, indefinite complaint, drop in operation efficiency, or feeling of malaise, etc.
Owner:MITSUBISHI TANABE PHARMA CORP

Herbal compositions for treating neurological diseases and improving memory impairment

The present invention relates to a composition for preventing or treating neurological diseases including an extract of Euphoria longan fruit, red sage and Gastrodia elata as an active ingredient. The composition of the present disclosure has a superior effect of inhibiting the activity of acetylcholinesterase (AChE), which hydrolyzes the neurotransmitter acetylcholine directly involved in impairment of cognitive function. In addition, the composition of the present disclosure is safe for the human body since the biologically safe extract of Euphoria longan fruit, red sage and Gastrodia elata is used as the active ingredient.
Owner:VIROMED CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products